UK-Wide Collaboration to Study Why ICIs Often Fail

The recently launched UK-based MANIFEST collaboration of academic, industry, and National Health Service groups will attempt to understand why less than half of patients respond to immunotherapy, research that could allow clinicians to predict whether a patient is likely to benefit from an immune checkpoint inhibitor before beginning treatment.